The assay, being developed in partnership with Johnson & Johnson, will complement computed tomography imaging by combining 26 genes and clinical variables for lung cancer detection.
Called the "Ccheck Prostate Cancer Confirmation" test, Anixa's assay integrates flow cytometry and machine learning to identify evidence of cancer in a person's bloodstream.
The team aims to fully commercialize the 28-biomarker panel for military veterans and civilians who show early symptoms of post-traumatic stress disorder.
The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.
The team believes users could apply the technology, combined with a predictive risk score, to complement imaging tools to screen for cancers in the clinical space.
The group will start a pilot study at Columbia University next week to sequence genes from 600 Parkinson's disease patients before expanding to a larger cohort.
The British team believes its classifier can identify men who will need treatment within five years, minimizing the need of repeated checkups for low-risk patients.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
The University of Arkansas researchers aim to commercialize the Cytophone platform, in development since 2003, by launching a startup in the next year.
By examining metagenomic data of bacterial species in a patient's gut, the researchers aim to improve diagnosis and long-term nutritional intervention and treatment.